Conte: Pfizer, AstraZeneca violated vaccine contracts - Breaking The News

Conte: Pfizer, AstraZeneca violated vaccine contracts

23 January

1 min read

EPA-EFE/ROBERTO MONALDO

Italian Prime Minister Giuseppe Conte accused on Saturday Pfizer Inc. and BioNTech SE, and AstraZeneca PLC of violating their contractual commitments by delaying deliveries of their vaccines against COVID-19.

Conte described the halt as "unacceptable" and an obstacle to the country's plan of vaccination, which the government created according to what the pharmaceutical companies promised the European Commission. He added Rome would use "all available legal tools" to make sure the manufacturers met their obligations.

Conte's comments come after both Pfizer and AstraZeneca confirmed delays in the delivery of their vaccines to the European Union.

conte coronavirus coronavirus vaccine pfizer astrazeneca biontech

Related Stocks

AstraZeneca

BioNTech

Pfizer

US attorney allegedly probes tip about Pfizer's vaccine timing

26 March

The United States Attorney's office is investigating a claim by the British pharmaceutical company GSK about the "delayed" announcement of the success of Pfizer's Covid vaccine in 2020, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.According to the report, Pfizer's former employee, Phil Dormitzer, who later became a senior scientist at Pfizer's rival company, GSK, told his colleagues at GSK that Pfizer delayed the...

China's VP He meets with Apple's Cook

24 March

Chinese Vice Premier and Central Financial and Economic Affairs Commission Office Director He Lifeng met with the heads of various major companies from North America to discuss the trade relations between Beijing and the United States, the Asian country's Commerce Ministry (MOFCOM) said in a statement issued on Monday.He met with the leaders of Pfizer Inc., Brookfield Corporation, Mastercard Inc., Cargill Incorporated, Corning Inc., and Apple Inc., with the...

AstraZeneca pledges $2.5B for R&D center in Beijing

21 March

AstraZeneca announced on Friday the investment of $2.5 billion in Beijing to establish its second strategic research and development (R&D) center in China and sixth worldwide. AstraZeneca projects its Beijing staff count will reach 1,700 personnel."This $2.5 billion investment reflects our belief in the world-class life sciences ecosystem in Beijing, the extensive opportunities that exist for collaboration and access to talent, and our continued commitment to China,"...

AstraZeneca to acquire EsoBiotec for up to $1B

17 March

AstraZeneca announced on Monday that it entered into a definitive agreement to acquire biotechnology company EsoBiotec SA for up to $1 billion in cash."We look forward to working with AstraZeneca, a global leader in drug development, to advance our shared goal of bringing transformative cost-effective cell therapies to more patients globally. By combining our expertise and resources, we can accelerate the development of our in vivo...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.